Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing
- PMID: 17200713
- PMCID: PMC1716223
- DOI: 10.1172/JCI30889
Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing
Abstract
Unraveling the mechanisms controlling remnant lipoprotein clearance is important, as these lipoproteins are highly atherogenic. The most critical molecule in this process is apoE, which mediates high-affinity binding of remnant lipoproteins to members of the LDL receptor (LDLR) family and cell-surface heparan sulfate proteoglycans (HSPGs), which have been shown to play major independent as well as cooperative roles in remnant lipoprotein clearance. While all the players may have been identified, our understanding of how they interact and function together continues to evolve. In this issue of the JCI, MacArthur et al. (see the related article beginning on page 153) demonstrated that HSPGs under normal physiological conditions are critically important in the clearance of remnant lipoproteins, independent of LDLR family members. The complexity of VLDL and chylomicron remnant clearance was exemplified by the studies of Jones et al., also in this issue (see the related article beginning on page 165). Despite defective clearance of LDL in mice with a deficiency in the adaptor protein controlling internalization of the LDLR, called autosomal recessive hypercholesterolemia (ARH), remnant lipoprotein clearance was not grossly abnormal. A likely explanation is that the abnormal LDLRs bind the remnants and then transfer them to another acceptor for internalization. While the studies clearly demonstrate that the LDLR-related protein 1 is not involved and suggest a role for an additional unidentified receptor, it remains a possibility that HSPGs are responsible for remnant uptake by hepatocytes in the presence of defective LDLR internalization.
Figures


Comment on
-
Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members.J Clin Invest. 2007 Jan;117(1):153-64. doi: 10.1172/JCI29154. J Clin Invest. 2007. PMID: 17200715 Free PMC article.
-
Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia.J Clin Invest. 2007 Jan;117(1):165-74. doi: 10.1172/JCI29415. J Clin Invest. 2007. PMID: 17200716 Free PMC article.
Similar articles
-
Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice.Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2065-74. doi: 10.1161/ATVBAHA.113.301637. Epub 2013 Jul 11. Arterioscler Thromb Vasc Biol. 2013. PMID: 23846497 Free PMC article.
-
Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members.J Clin Invest. 2007 Jan;117(1):153-64. doi: 10.1172/JCI29154. J Clin Invest. 2007. PMID: 17200715 Free PMC article.
-
Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans.J Lipid Res. 1995 Mar;36(3):583-92. J Lipid Res. 1995. PMID: 7539827
-
Hepatic heparan sulfate proteoglycans and endocytic clearance of triglyceride-rich lipoproteins.Prog Mol Biol Transl Sci. 2010;93:213-33. doi: 10.1016/S1877-1173(10)93010-X. Prog Mol Biol Transl Sci. 2010. PMID: 20807647 Review.
-
Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E.J Lipid Res. 1999 Jan;40(1):1-16. J Lipid Res. 1999. PMID: 9869645 Review.
Cited by
-
SULF2 strongly prediposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitus.Obesity (Silver Spring). 2014 May;22(5):1309-16. doi: 10.1002/oby.20682. Epub 2014 Jan 9. Obesity (Silver Spring). 2014. PMID: 24339435 Free PMC article.
-
Triglyceride-rich lipoprotein binding and uptake by heparan sulfate proteoglycan receptors in a CRISPR/Cas9 library of Hep3B mutants.Glycobiology. 2019 Jul 19;29(8):582-592. doi: 10.1093/glycob/cwz037. Glycobiology. 2019. PMID: 31094413 Free PMC article.
-
Polyhedral 3D structure of human plasma very low density lipoproteins by individual particle cryo-electron tomography1.J Lipid Res. 2016 Oct;57(10):1879-1888. doi: 10.1194/jlr.M070375. Epub 2016 Aug 18. J Lipid Res. 2016. PMID: 27538822 Free PMC article.
-
Triglycerides and cardiovascular risk.Curr Cardiol Rev. 2009 Aug;5(3):216-22. doi: 10.2174/157340309788970315. Curr Cardiol Rev. 2009. PMID: 20676280 Free PMC article.
-
Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles.Mol Ther Nucleic Acids. 2013 Dec 17;2(12):e139. doi: 10.1038/mtna.2013.66. Mol Ther Nucleic Acids. 2013. PMID: 24345865 Free PMC article.
References
-
- Mahley R.W., Ji Z.-S. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. . 1999;40:1–16. - PubMed
-
- Mahley R.W., Huang Y., Rall S.C. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes. J. Lipid Res. . 1999;40:1933–1949. - PubMed
-
- Mahley R.W., Weisgraber K.H., Innerarity T.L., Rall S.C. Genetic defects in lipoprotein metabolism. Elevation of atherogenic lipoproteins caused by impaired catabolism. JAMA. . 1991;265:78–83. - PubMed
-
- Mahley, R.W., and Rall, S.C., Jr. 1995. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. InThe metabolic and molecular bases of inherited disease. 7th edition. Volume 2. C.R. Scriver, A.L. Beaudet, W.S. Sly, and D. Valle, editors. McGraw-Hill. New York, New York, USA. 1953–1980.
-
- Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. . Science. . 1988;240:622–630. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous